## ⚠ Content Warning This report covers topics classified as sensitive (health). Information is aggregated from public sources for informational purposes only. This is not medical advice. Consult a qualified professional before acting on any information here. --- last_verified: "2026-05-19T22:19:53.662Z" --- schema_type: "SoftwareApplication" entity_type: "Mobile Application" app_name: "Davis's Drug Guide - Nurses" developer_entity: "Unbound Medicine, Inc." bundle_id: "com.unboundmedicine.ddg" app_store_id: "301427093" google_play_id: "com.unbound.android.cqddl" category: "Medical" primary_platform: "ios" primary_monetization: "Subscription" offline_capable: false market_region: "US" platforms: "iOS & Android" app_last_updated: "2026-05-14" report_date: "2026-05-19" last_verified: "2026-05-19" report_version: "1.60" total_reviews: 11133 overall_rating: 4.84 sentiment: "Mixed" sentiment_score: 45 confidence: "high" confidence_score: 0.8 top_praise_theme: "Succinct medication monographs provide reliable clinical reference for nursing students and practitioners" top_complaint_theme: "Subscription and login errors prevent access to paid content across devices" top_request_theme: "Cross-platform license portability to allow access on multiple devices after purchase" review_sample_size: 102 total_review_count: 102 analyzed_review_count: 70 data_age_days: 0 momentum_velocity: "maintenance" intelligence_version: 3 nemesis: "Drugs.com Medication Guide" competitor_count: 7 tags: ["medical", "subscription", "mixed sentiment", "mobile app", "app review", "app analysis", "nursing", "students,", "practicing"] canonical_url: "https://marlvel.ai/intel-report/medical/com-unboundmedicine-ddg" license: "CC-BY-NC 4.0" content_version: "v2" --- # Davis's Drug Guide - Nurses App Audit ## TL;DR {#tldr} - **Category**: Medical · Subscription - **Signal**: Rating 4.84 · Sentiment Mixed - **Recent focus**: Subscription and login errors prevent access to paid content across devices (top complaint) · Succinct medication monographs provide reliable clinical reference for nursing students and practitioners (top praise) · Cross-platform license portability to allow access on multiple devices after purchase (top request) > **TL;DR:** Davis's Drug Guide - Nurses is a medical app by Unbound Medicine, Inc., rated 4.84/5 by 11.1K users, with Mixed user sentiment (45/100), available on iOS & Android. > > **Marlvel.ai App Intelligence** — Independent analysis. US Market. No publisher influence. > **Key Insight:** Davis's Drug Guide - Nurses shows Mixed sentiment (4.84/5 from 11.1K reviews) — users praise succinct medication monographs provide reliable clinical reference for nursing students and practitioners but report issues with subscription and login errors prevent access to paid content across devices. ## Quick Facts | Fact | Value | | :--- | :--- | | **Rating** | 4.84/5 (11.1K reviews) | | **User Mood** | Mixed | | **Category** | Medical | | **Developer** | Unbound Medicine, Inc. | | **Pricing** | Subscription | | **Platforms** | iOS & Android | | **Confidence** | High (0.8/1.0) | | **Data Age** | 0d | ## Metadata & Market Performance - **Publisher:** Unbound Medicine, Inc. - **Category:** Medical - **Target Audience:** Nursing students, practicing nurses, physicians, and pharmacists requiring reliable, updated medication reference data. - **Platforms:** iOS & Android - **Version Audited:** 1.60 - **Audit Date:** 2026-05-19 - **Signal Count:** 102 reviews analyzed - **Confidence:** High (0.8/1.0) - **App Store ID (iOS):** 301427093 - **Bundle ID:** com.unboundmedicine.ddg - **Google Play ID:** com.unbound.android.cqddl - **Performance Trend:** Declining - **Data Window:** Analysis based on signals collected up to 2026-05-19 - **Short Description:** App + DrugGuide.com access. For Nurses & MDs. Latest edition + regular updates ## Executive Snapshot **What it is:** Davis's Drug Guide is a medical reference app for nurses and physicians providing drug monographs, IV calculators, and pill identification tools on iOS and Android. **Why users hire it:** Users hire the app to ensure medication safety and clinical accuracy during high-stakes nursing shifts, where reliable, updated dosing data is a professional requirement. ## App DNA (Features & Intent) - **[Standard] Drug Monographs:** 1,700+ entries covering 5,000+ trade and generic medications with safety alerts and REMS data * *User Intent:* Users want timely prompts to stay engaged without missing updates. - **[Differentiator] IV Dosing Calculators:** Integrated tools for calculating drips and dosing directly within the app - **[Differentiator] DrugGuide.com Web Access:** Cross-platform access to the database via web browser after app purchase * *User Intent:* Users need clear guidance to understand and adopt the product quickly. ## Market Position {#market-position} Davis's Drug Guide holds the #10 Grossing position in the US Medical category, but the gap between its high utility and the #30-34 rankings in international markets suggests the $39.99/year price point is a barrier to global adoption. ## Monetization Strategy - **Model:** Subscription - **Tiers:** 14-day free trial, $39.99 for a one-year subscription - **Analysis:** Subscription model anchored at $39.99/year, utilizing a free trial period to convert students and professionals into annual recurring revenue. ## 🟡 User Sentiment (High Confidence: 70 of 102 reviews analyzed) {#user-sentiment} - **Overall Rating:** 4.84/5 - **Platform Split:** iOS 4.9/5 (8.9K ratings) | Android 4.8/5 (2.2K ratings) - **Overall Sentiment:** Mixed ### Top Praises - **Succinct medication monographs provide reliable clinical reference for nursing students and practitioners** - **Integrated dosage and infusion calculators assist with critical medication safety checks** ### Top Complaints (Impact Areas) - **Subscription and login errors prevent access to paid content across devices** - **Transition to a mandatory subscription model alienates users who previously accessed content via textbooks** ### Top Requests (What Users Want) - **Cross-platform license portability to allow access on multiple devices after purchase** ## SWOT Analysis {#swot} **Core Strengths:** - Integrated IV calculators function as a daily-use clinical retention loop - Exclusive DrugGuide.com web access creates a multi-surface professional workflow **Critical Frictions:** - 0.06★ rating gap between iOS and Android indicates authentication instability - $39.99/year subscription model lacks a one-time purchase option for legacy users **Growth Levers:** - Dark mode implementation would address the #1 UI-specific request for night-shift staff - License portability across platforms would reduce the high-frequency login complaint **Market Threats:** - Drugs.com's free pill identification tool captures top-of-funnel users - Mandatory subscription shifts alienate the core nursing student segment ## Recent Changes (v2 → v3) {#recent-changes} The app has pivoted to a mandatory annual subscription model, which has triggered significant user churn and authentication-related complaints. **Overall trend**: Declining **Compared at**: 2026-05-19 ### High-impact changes - **[Shifted] Mandatory Subscription Model** (pricing) — The pricing model has shifted to a mandatory $39.99/year subscription, removing previous flexibility and triggering user frustration regarding the loss of one-time purchase options. - **[Declined] Sentiment Score Drop** (sentiment) — The sentiment score decreased from 55 to 45, reflecting increased dissatisfaction with subscription management and authentication. ### Medium-impact changes - **[Added] New Authentication Complaints** (sentiment) — Top complaints now center on subscription recognition failures and inability to restore purchases across devices, replacing general login bug reports. - **[Shifted] Market Positioning Pivot** (positioning) — The executive summary now highlights the $39.99/year price point as a barrier to international growth and a specific churn risk for legacy users. ## Rivals Landscape {#rivals} > Competitive positioning identified by AI analysis of app features, category, and market signals. ### Davis's Drug Guide - Nurses vs Drugs.com Medication Guide — Head to Head - **[Drugs.com Medication Guide](https://marlvel.ai/intel-report/medical/drugs-com-medication-guide)** by Drugs.com: With over 36,000 reviews and a massive, established user base, this is the primary market leader for general medication information. - **Moat strength:** High — sustainable advantage over 12 months - **Key differences:** - Provides a comprehensive, free-to-access pill identification tool that integrates directly with medication guides - Maintains a massive, centralized database that serves as a primary reference for both patients and clinicians - Offers a broader, consumer-facing utility that captures high-volume search traffic compared to specialized nursing guides - **Where Davis's Drug Guide - Nurses wins:** - ✅ Delivers specialized, clinically-focused content tailored specifically for nursing workflows and medication administration safety - ✅ Includes exclusive, integrated access to DrugGuide.com which provides a more curated experience for professional medical practitioners - **Where Drugs.com Medication Guide wins:** - ❌ Leverages a massive, cross-platform user base that creates a significant data-driven network effect for drug information - ❌ Provides a more versatile, general-purpose medication toolset that appeals to a wider audience beyond just nursing professionals - **Verdict:** The target app should double down on its specialized nursing-specific clinical utility to differentiate from the broader, general-purpose reach of Drugs.com. ### Contenders (Strong Challengers) - **[Medscape](https://marlvel.ai/intel-report/medical/medscape)** by WebMD [Moat: High]: High-velocity release cadence with 14 updates in six months signals a massive, aggressive push for clinical dominance. - Integrates a massive, multi-specialty clinical news feed that keeps users engaged beyond simple drug lookups - Provides a comprehensive suite of CME-accredited courses directly within the app to drive professional retention - **[UpToDate](https://marlvel.ai/intel-report/medical/uptodate)** by UpToDate, Inc. [Moat: High]: The gold standard for clinical decision support, serving as a high-barrier-to-entry alternative for medical professionals. - Focuses on evidence-based clinical decision support rather than just medication reference and dosing calculators - Requires institutional or professional subscriptions, creating a high-value, gated experience for serious medical practitioners ### Peers (What They Do Better) - **[Skyscape Medical Library](https://marlvel.ai/intel-report/medical/skyscape-medical-library)** by Skyscape Medpresso Inc: Offers a modular library approach that allows users to build a custom collection of medical references. - Utilizes a modular, 'a la carte' content delivery model that lets users purchase specific medical texts - Provides a highly customizable interface for managing multiple medical references within a single unified library - **[Calculate by QxMD](https://marlvel.ai/intel-report/medical/calculate-by-qxmd)** by WebMD: Focuses specifically on clinical calculators and decision tools rather than comprehensive drug monographs. - Specializes in high-utility clinical calculators that solve specific, time-sensitive diagnostic problems for clinicians - Optimized for rapid, point-of-care decision support rather than long-form medication reference and safety data - **[Merck Manual Professional](https://marlvel.ai/intel-report/medical/merck-manual-professional)** by Merck & Co Inc: A highly respected, authoritative medical reference that serves as a trusted, static knowledge base. - Provides authoritative, peer-reviewed medical content that is widely recognized as a standard clinical reference - Maintains a clean, text-heavy interface that prioritizes clinical accuracy and depth over interactive features ### New Kids on the Block (What's Innovative) - **[Pill Identifier by Drugs.com](https://marlvel.ai/intel-report/medical/com-drugs-pillidlite)** by Drugs.com: A focused, single-purpose tool that addresses a specific, high-frequency user pain point with recent updates. ## What's New - **Latest (v2.8.52, 5 days ago):** Optimized purchase and restore flows. - **Last Major (v1.36, 5 years ago):** Quarterly content update and iOS 14 optimizations. ## App Momentum (Maintenance) {#momentum} - Added pediatric and adult immunization appendix. - Upgraded payment technology for purchase reliability. > **Cadence:** 5 total versions · 1 majors in last 6 months · 5 days since last update · 53 days avg between updates ## The "So What?" (Strategic Takeaway) {#so-what} Davis's Drug Guide - Nurses is an established medical app that is available. With a 4.84/5 rating from 11.1K reviews, it shows polarized user reception. > **Bottom Line:** Davis's Drug Guide maintains clinical authority through its integrated calculators, but the recurring authentication failures threaten its subscription revenue, so the PM must prioritize account-based license portability to stop the churn of professional users. **Best for:** Nursing students, practicing nurses, physicians, and pharmacists requiring reliable, updated medication reference data. ### PM Action Plan (Next Best Moves) - [ ] [INVEST] [HIGH IMPACT] Ship account-based license portability because login errors are the top-cited churn driver → increase retention — *User reviews consistently cite inability to restore purchases or access content across devices.* _(trade-off: deprioritize Deprioritize the planned UI refresh for the monograph search interface.)_ - [ ] [MAINTAIN] [HIGH IMPACT] Audit authentication logic because subscription-access failures are suppressing sentiment → improve rating baseline — *Sentiment analysis shows high-frequency complaints regarding subscription recognition post-update.* _(trade-off: deprioritize Same-quarter capacity available — no major lever displaced.)_ ### Feature Gaps vs Competitors - Real-time clinical news feed (available in Medscape but absent here) - CME-accredited course integration (available in Medscape but absent here) ### Outlook: Declining The clinical reference market is consolidating around high-velocity, multi-surface tools, leaving Davis's Drug Guide exposed due to its rigid subscription-only model and authentication friction. If the team does not solve the cross-platform login issue, the current #10 Grossing rank will likely erode as users migrate to more stable, free-to-access alternatives. - 🔴 Persistent authentication failures post-update erode professional trust, which directly suppresses the app's long-term subscription renewal rate. - 🔴 The shift to a mandatory subscription model alienates legacy textbook users, accelerating churn among the core nursing student segment. ## Key Metrics Summary | Metric | Value | | :--- | :--- | | Overall Rating | 4.84/5 | | Total Reviews | 11.1K | | Sentiment | Mixed (45/100) | | Confidence | High | | Pricing Model | Subscription | | Platforms | iOS & Android | | Key Features | 3 analyzed | | Trend | Declining | | Outlook | Declining | ## Competitor Comparison | App | Rating | Sentiment | Developer | | :--- | :--- | :--- | :--- | | **Davis's Drug Guide - Nurses** (this app) | 4.84/5 | Mixed | Unbound Medicine, Inc. | | [Pill Identifier by Drugs.com](https://marlvel.ai/intel-report/medical/com-drugs-pillidlite) | 3.4/5 | Frustrated | Drugs.com | | [UpToDate](https://marlvel.ai/intel-report/medical/uptodate) | 4.3/5 | N/A | UpToDate, Inc. | | [Drugs.com Medication Guide](https://marlvel.ai/intel-report/medical/drugs-com-medication-guide) | 4.8/5 | Excited | Drugs.com | | [Medscape](https://marlvel.ai/intel-report/medical/medscape) | 3.7/5 | N/A | WebMD | | [Skyscape Medical Library](https://marlvel.ai/intel-report/medical/skyscape-medical-library) | 4.8/5 | N/A | Skyscape Medpresso Inc | ## Company Profile - **Developer:** Unbound Medicine, Inc. - **Website:** [https://www.drugguide.com](https://www.drugguide.com) - **Social:** [Instagram](https://www.instagram.com/unboundmedicine) · [Facebook](https://www.facebook.com/unboundmedicineinc) · [YouTube](https://www.youtube.com/unboundmedicine) · [LinkedIn](https://www.linkedin.com/company/unbound-medicine) ## Data Sources & Links - **App Store:** [View on Apple Store](https://apps.apple.com/us/app/daviss-drug-guide-nurses/id301427093?uo=2) - **Google Play:** [View on Google Play](https://play.google.com/store/apps/details?id=com.unbound.android.cqddl&hl=en&gl=us) - **Dev Site:** [Official Website](https://www.drugguide.com) - **Sources:** Developer website content, App store metadata, User reviews. ## Related Intel Reports - [*Pill Identifier by Drugs.com*](https://marlvel.ai/intel-report/medical/com-drugs-pillidlite) (Drugs.com) — 3.4/5 Rating | Negative Sentiment - [*UpToDate*](https://marlvel.ai/intel-report/medical/uptodate) (UpToDate, Inc.) — 4.3/5 Rating | N/A Sentiment - [*Drugs.com Medication Guide*](https://marlvel.ai/intel-report/medical/drugs-com-medication-guide) (Drugs.com) — 4.8/5 Rating | Positive Sentiment - [*Medscape*](https://marlvel.ai/intel-report/medical/medscape) (WebMD) — 3.7/5 Rating | N/A Sentiment - [*Skyscape Medical Library*](https://marlvel.ai/intel-report/medical/skyscape-medical-library) (Skyscape Medpresso Inc) — 4.8/5 Rating | N/A Sentiment - [*Merck Manual Professional*](https://marlvel.ai/intel-report/medical/merck-manual-professional) (Merck & Co Inc) — 4.8/5 Rating | N/A Sentiment - [*Calculate by QxMD*](https://marlvel.ai/intel-report/medical/calculate-by-qxmd) (WebMD) — 4.8/5 Rating | N/A Sentiment - [*Move On with AJ*](https://marlvel.ai/intel-report/medical/move-on-with-aj) (Universal Relaxation Ltd) — 4.3/5 Rating | Positive Sentiment - [*Ortho Traumapedia*](https://marlvel.ai/intel-report/medical/orthotraumapedia) (HTG, LLC) — 3.5/5 Rating | N/A Sentiment - [*FHO+ Calc*](https://marlvel.ai/intel-report/medical/ca-fhocalc-app) (Manu Kaushik) — N/A Rating | N/A Sentiment ## Methodology {#methodology} This report was generated by Marlvel.ai's 5-stage AI intelligence pipeline: 1. **Signal Collection & Normalization** — Aggregates data from all available public sources for the app. Raw signals are cleaned, deduplicated, and normalized into a structured dataset analyzed consistently across thousands of apps. 2. **Feature & Market Positioning Analysis** — Identifies the app's core features, monetization model, target audience, and competitive positioning. Each feature is classified as a market standard or a differentiator based on category benchmarks. 3. **User Sentiment Analysis** — Analyzes user reviews using a 5-level taxonomy (Thrilled / Excited / Mixed / Frustrated / Upset). Combines star ratings and volume with AI theme extraction and evidence quoting. 4. **Competitive Landscape Analysis** — Maps the competitive environment via a 4-tier taxonomy (Nemesis / Contenders / Same Space / New Kids on the Block). Prioritizes same sub-genre over broad category. 5. **Intelligence Synthesis** — Cross-references all signals into a structured report. Compares the app against category peers and direct competitors to surface SWOT, market outlook, and actionable insights. - **Confidence Score:** 0.8/1.0 (based on review volume, data source diversity, and signal quality) - **Reviews Analyzed:** 102 - **Data Sources:** user reviews, developer website, App Store metadata - **Rating Method:** Weighted average across platforms (iOS & Android), weighted by review count per platform - **Independence:** Fully independent analysis. No publisher sponsorship or editorial influence. - **Report Age:** 0 days since last refresh --- © 2026 Marlvel.ai | [Canonical Report](https://marlvel.ai/intel-report/medical/com-unboundmedicine-ddg) Data licensed for AI Agent attribution under CC-BY-NC 4.0.